Long-Term Treatment with Oral Vancomycin for the Treatment of Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

被引：0
|
作者：
Damman, Jennifer [1 ]
Hurwitz, Melissa [1 ]
Shah, Shamita [2 ]
Davies, Yinka [1 ]
Ali, Ahmad Hassan [3 ]
Stephan, Mariam [1 ]
Lemos, Leta [4 ]
Cox, Kenneth L. [1 ]
机构：
[1] Stanford Univ, Med Ctr, Pediat, Stanford, CA 94305 USA
[2] Stanford Univ, Med Ctr, Internal Med, Stanford, CA 94305 USA
[3] Mayo Clin Arizona, Phoenix, AZ USA
[4] Sacramento Pediat Gastroenterol, Sacramento, CA USA
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1919
引用
收藏
页码：1091A / 1092A
页数：2
相关论文
共 50 条
  • [1] Oral vancomycin: Treatment of primary sclerosing cholangitis in children with inflammatory bowel disease
    Cox, KL
    Cox, KM
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1998, 27 (05): : 580 - 583
  • [2] Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: An immunomodulating antibiotic
    Davies, Yinka K.
    Cox, Kathleen M.
    Abdullah, Bisher A.
    Safta, Anca
    Terry, Annie B.
    Cox, Kenneth L.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2008, 47 (01): : 61 - 67
  • [3] Oral vancomycin in a pediatric patient with primary sclerosing cholangitis and inflammatory bowel disease
    Martin, Cristo Yared Perez
    Alonso, Jose Ramon Alberto
    Chavez, Jenifer Gonzalez
    Ruiz, Maria Pilar Diaz
    Gonzalez, Marta Suarez
    Alonso, Javier Merino
    FARMACIA HOSPITALARIA, 2023, 47 (06) : T297 - T299
  • [4] Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
    Kim, You Sun
    Hurley, Edward H.
    Park, Yoojeong
    Ko, Sungjin
    INTESTINAL RESEARCH, 2023, 21 (04) : 420 - 432
  • [5] Outcomes of oral vancomycin therapy in patients with primary sclerosing cholangitis and inflammatory bowel disease
    Tan, D.
    Demase, K.
    Little, R.
    Ardalan, Z.
    Taylor, K.
    Sparrow, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 143 - 144
  • [6] Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis
    Sannaa, Wassel
    Almasry, Mazen
    Peedikayil, Mustafa
    Grimshaw, Alyssa A.
    Attamimi, Mashary
    Almutairdi, Abdulelah
    Al-Bawardy, Badr
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2025, 18
  • [7] The Effectiveness of Oral Vancomycin on Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis: A Systematic Review
    Arbabzada, Naik
    Dennett, Liz
    Meng, Guanmin
    Peerani, Farhad
    INFLAMMATORY BOWEL DISEASES, 2024,
  • [8] Long-term oral vancomycin for refractory inflammatory bowel diseases without Clostridium difficile infection: Lessons from primary sclerosing cholangitis
    Du, Wei
    Han, Weili
    Dong, Jiaqiang
    MEDICAL HYPOTHESES, 2020, 144
  • [9] ORAL VANCOMYCIN AS AN EFFECTIVE MONOTHERAPY FOR THE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS
    Tsay, Cynthia
    Lemos, Leta
    Scudiere, Jennifer R.
    Cox, Kenneth
    Davies, Yinka
    GASTROENTEROLOGY, 2019, 156 (06) : S1325 - S1325
  • [10] An 'Adaptive Treatment Strategy' for Oral Vancomycin in Patients with the Orphan Disease Primary Sclerosing Cholangitis
    Shah, Ayesha
    Tabibian, James
    Buness, Cynthia
    Holtmann, Gerald J.
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (10) : 3608 - 3613
12345